Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatment of patients with seasonal allergic rhinoconjunctivitis due to grass pollen

Trial Profile

A multi-centre, randomised, double blind, placebo controlled study to determine the optimal effective and safe dose of Pollinex Quattro Grass 1.0 mL (Allergy Therapeutics, (UK) Ltd.) for the treatment of patients with seasonal allergic rhinoconjunctivitis due to grass pollen

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis
  • Focus Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 25 Feb 2019 Results assessing a strong dose-response Using a Conjunctival Provocation Test, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 25 Feb 2019 Results assessing Strong Dose-response On Immunoglobulin Makers, presented at the 2019 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 25 Jun 2018 According to an Allergy Therapeutics media release, company announces the publication of positive data in the journal Immunotherapy.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top